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Running Title:  The Vascular Effects of Intra-Arterial Nitrite in Heart Failure Patients. 
 
 
Abbreviations: 
 
Nitrite (NO2-) 
Nitric Oxide (NO) 
Sodium nitrite (NaNO2) 
Forearm blood flow (FBF) 
Unstressed Venous Volume (UVV) 
Forearm venous volume (FVV) 
Protein-bound Nitric Oxide (RXNO) 
Glyceryl Trinitrate (GTN) 
Half Maximal Effective Concentration (EC50) 
Ethylenediamine Tetraacetic Acid (EDTA) 
Aldehyde Dehydrogenases (ALDH)   
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SUMMARY 
Background and Purpose: Nitrite (NO2-) has recently been shown to represent a potential 
source of nitric oxide (NO), in particular under hypoxic conditions. The aim of the current 
study was to compare the hemodynamic effects of nitrite in healthy volunteers and patients 
with stable congestive heart failure (CHF).  
Experimental Approach:  The acute hemodynamic effects of brachial artery infusion of 
nitrite (0.31 to 7.8µmoles/min) was assessed in normal subjects (n=20) and CHF patients 
(n=21).  
Key Results:  NO2- infusion was well tolerated in all subjects. Forearm blood flow (FBF) 
increased markedly in CHF-patients at NO2- infusion rates which induced no changes in 
normal subjects (ANOVA: F=5.5; p=0.02). Unstressed venous volume (UVV) increased even 
with the lowest NO2- infusion rate in all subjects (indicating venodilation), with CHF patients 
being relatively hyporesponsive compared with normal subjects (ANOVA: F=6.2; p=0.01). 
There were no differences in venous blood pH or oxygen concentration between groups or 
during NO2- infusion. Venous plasma NO2- concentrations were lower in CHF-patients at 
baseline, and rose substantially less with NO2- infusion, without incremental oxidative 
generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein-
bound NO concentrations were lower in CHF-patients than normal subjects at baseline.  This 
difference was attenuated during NO2- infusion. Prolonged nitrite exposure in-vivo did not 
induce oxidative stress, nor did it induce tolerance in vitro. 
Conclusions and Implications:  The findings of arterial hyper-responsiveness to infused 
NO2- in CHF-patients, with evidence of accelerated transvascular NO2- clearance A
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(presumably with concomitant NO release) suggests that NO2- effects may be accentuated in 
such patients. These findings provide a stimulus for the clinical exploration of NO2- as a 
therapeutic modality in CHF. 
 
Keywords: Sodium Nitrite, vascular effects, heart failure 
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INTRODUCTION 
Nitrite (NO2-), present in plasma at submicromolar concentrations, has been regarded in the 
past as a relatively inert product of nitric oxide (NO) catabolism and dietary nitrate/nitrite 
ingestion. Nitrite is also generated as a component of organic nitrate metabolism. It is now 
clear that NO2- can indeed exert vasodilator effects, possibly via reduction to NO (Cosby et 
al., 2003; Crawford et al., 2006). 
Although the mechanism(s) of bioactivation remain incompletely understood, a number of 
reductases have been shown to “reactivate” NO from NO2-, independent of endothelial nitric 
oxide synthase (eNOS) activity (Baker et al., 2007;Webb et al., 2008).  This process appears 
to be markedly potentiated in hypoxia, although once again it is not clear what mechanism(s) 
underlie this (Maher et al., 2008). The implication is that exogenous administration of NO2- 
represents a means of selective release of NO (and hence vasodilatation) to hypoxic (and 
presumably ischaemic) tissues, with minimal risk of inducing the “steal” phenomenon and no 
dependence on intact endothelial function. Thus NO2- represents a potential treatment for 
conditions such as limb and myocardial ischaemia, and congestive heart failure. 
A desirable characteristic of a vasodilator agent for potential use in the management of 
acutely decompensated heart failure is that it exerts marked venodilator, rather than arteriolar 
dilating effects.  Salutary consequences of selective venodilatation include relief of 
congestive symptoms without significant risk of precipitating symptomatic hypotension. 
Specifically, venodilator agents ameliorate the phenomenon of diastolic ventricular 
interaction, thus increasing cardiac output and thereby organ perfusion (Atherton et al,. 
1997;Dupuis et al., 1990; Williams and Frenneaux, 2006). 
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In this regard, organic nitrates such as glyceryl trinitrate (GTN) are frequently utilized in the 
management of acute heart failure with pulmonary congestion. Although organic nitrate-
based therapy exerts prominent venodilator effects (Manyari et al., 1993; Muir and Nolan, 
1991) and appears to have a number of advantages over a diuretic-based treatment regimen in 
such patients, there is no evidence that NO release from GTN is hypoxia-selective. 
Furthermore, therapy with GTN and other organic nitrates not only suffers from the problem 
of attenuation of effect during prolonged therapy (nitrate tolerance and pseudo-tolerance) 
(Daiber et al., 2005; Munzel et al., 2005), but also exhibits the phenomenon of NO resistance 
(de novo hyporesponsiveness to all sources of NO) in the presence of CHF, despite infusion 
at very high rates (Anderson et al., 2004; Chirkov et al., 1999; Chirkov et al., 2001).  
Moreover, the arteriolar vasodilation induced by organic nitrates can lead to deleterious 
reductions in systemic blood pressure, often accompanied by throbbing headache. 
We have previously described the local forearm vascular responses to infused NO2- in normal 
subjects, documenting a marked venodilation and modest arteriolar vasodilation under 
normoxic conditions.  However, during hypoxia, there was selective potentiation of arterial 
vasodilation (Maher et al., 2008). 
In the current study, we have compared vasomotor responsiveness to NO2- in stable CHF 
patients and in normal subjects, relating response to concomitant plasma NO2- concentrations. 
We theorised that CHF patients might largely circumvent the problem of NO resistance at the 
arterial level by virtue of the potentiating effect of tissue hypoxia on NO2- bioactivation.  As 
such, the primary null hypothesis was that the vasomotor effects of nitrite would not vary 
between patients with CHF and normal subjects. The secondary hypothesis was that the 
pharmacokinetics of nitrite would not differ significantly between the two groups. Additional A
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experiments were performed to determine whether prolonged nitrite exposure might result in 
incremental oxidative stress and/or induce the development of tolerance. 
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METHODS 
 
Subject selection: 
The study involved a comparison between patients with stable NYHA Class II-III CHF 
(n=21) and healthy volunteers (n=20).  CHF patients were recruited from an ‘advanced heart 
failure and cardiomyopathy’ outpatient clinic.  Among CHF patients, contraindications to 
study entry were long-acting nitrate therapy, symptomatic hypotension and clinically 
significant hepatic or renal dysfunction. None of the normal subjects had any known coronary 
risk factors, and none was taking cardioactive medications or vitamin supplements.  The 
study was approved by the Local Research Ethics Committee and all patients gave written 
informed consent. The study conformed to the principles of the Declaration of Helsinki.  
Subjects had consumed a light breakfast and abstained from caffeine drink intake for at least 
6 hours. Pre-study dietary nitrate/nitrite intake was not modified. 
 
Experimental Protocol: 
(a) Instrumentation: 
Subjects rested supine in a dedicated vascular laboratory and brachial artery cannulation was 
performed as previously described (Maher et al., 2008). 
 
(b) Hemodynamic assessment: 
The principal hemodynamic investigations performed were serial determination of unstressed 
forearm venous volume (UVV) as an index of venodilator response, and forearm blood flow A
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(FBF) as an index of arteriolar response to infused NO2-. Forearm venous volume (FVV) was 
assessed utilising radionuclide plethysmography as previously described (Schmitt et al., 
2002) and FBF was measured utilizing strain-gauge-plethysmography, as previously 
described (Gunaruwan et al., 2002).  Results were expressed relative to baseline values and 
those in the infused arm, corrected for changes in the non-infused arm. 
 
(c) NO2- infusion: 
Figure 1 is a schematic of the overall experimental design. After determination of baseline 
data, nitrite was infused into the non-dominant brachial artery. Infusion rates were 
0.31µmoles/min for 30 minutes, thereafter increasing to 0.78µmoles/min, 3.1µmoles/min and 
7.8 µmoles/min, each for further 30-min infusion periods. Changes in hemodynamic 
parameters were measured 5, 12 and 20 minutes after initiation of each infusion rate. 
 
(d) Blood sampling/analysis: 
Blood was withdrawn via venous cannulae in both arms at baseline and after the conclusion 
of each infusion.  Blood gas analysis was performed for pH, oxygen and methaemoglobin 
concentrations.  (Bayer Rapidlab 865). Blood for determination of venous plasma NO2-, 
nitrate and protein-bound NO (RXNO) concentrations was taken into EDTA tubes and 
immediately centrifuged (200rpm for 10 minutes at 4°C). Samples were stored at -80°C prior 
to assay.  Plasma NO2-, nitrate and protein-bound NO content were determined via ozone-
based chemiluminescence (Pinder et al., 2009) or HPLC (Rassaf et al., 2002) as previously 
described.  
 
(e) Assessment of Nitrite Clearance in Human Plasma in vitro: A
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To ensure that nitrite clearance in vitro did not vary between normal subjects and patients, 
experiments were performed in which fresh venous blood (EDTA) from normal and CHF 
subjects was spiked with sodium nitrite in vitro to final concentrations of 2 and 20µM; after 
spiking samples were incubated under gentle agitation at 37ºC with aliquots being removed 
after 1, 2, 5, 10, 20 and 60 minutes prior to addition of N-ethylmaleimide (10 mM), 
centrifugation and assay.   
 
 
(f) Reagents: 
Sodium nitrite was purchased from Martindale Pharmaceuticals, UK. HPLC-grade nitrite-free 
water (Fisher Scientific) was utilised for extractions and dilutions. 
 
(g)  In Vitro Tolerance induction experiments: 
In vitro studies were performed to address the possibility that prolonged infusion of nitrite 
might induce tolerance to itself and/or cross-tolerance to GTN.  Segments of saphenous veins 
discarded after bypass grafting were collected from patients undergoing non-emergent 
coronary artery bypass grafting who had not received long-acting nitrates for at least 24 
hours, placed in ice-cold Krebs solution, cleaned and cut into 2-3 mm segments.  For vascular 
reactivity studies, venous segments were suspended under tension in 15-ml organ baths 
containing Krebs solution at 37˚C. Resting tension was set at 1gm, as previously described 
(Sage et al., 2000) and segments were equilibrated for 60 minutes before being constricted 
with 120 mmol/L KCl; vessel segments in which constriction was less than 1g were 
discarded.  After a further 30 minutes of washout, the segments were pre-constricted with 
phenylephrine to produce 70% of maximal tension. Once contractile response had reached a A
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plateau, each segment was exposed to increasing concentrations of sodium nitrite (NaNO2) 
(4x10-9 to 1.2x10-2 M) and GTN (4x10-9 to 1.2x10-5 M) in order to obtain cumulative 
vasodilator concentration-response curves. The order of administration of NaNO2 and GTN 
was randomised. A washout period of 30 minutes was allowed between vasodilator response 
curves. 
Tolerance induction experiments were performed via incubation of venous segments in 10-2 
M NaNO2 under resting tension for 45 minutes. After a further washout period of 30 minutes, 
NaNO2 and GTN concentration-response curves were repeated, again in random order. In 
each experiment, control vessels were utilised in order to exclude spontaneous changes in 
responsiveness to either vasodilator. 
Vascular relaxation responses to NaNO2 and GTN were compared before and after prolonged 
NaNO2 exposure, via curve-fitting of individual concentration response data to obtain EC50 
values for each curve. In the case of NaNO2 administration, which yielded bi-sigmoidal 
concentration-response curves, EC50 values were calculated from the low-affinity, high-
capacity component of the response. As EC50 data were normally distributed, these were 
compared via paired t tests. 
(h) Assessment of nitrite infusion upon levels of oxidative stress: 
Heart failure patients (n=15) were exposed to saline infusion (20min), followed by two 
incremental doses of nitrite (7.84 nM and 7.84 µM; 20 min intravenous infusion for each 
dose) under normoxic conditions. The patients were then exposed to 12% hypoxia for 20 min 
and infused with 7.84 µM nitrite. At the end of each infusion, blood samples were taken for 
plasma 8-isoprostane analysis.  
(i) Assessment of oxidative stress:  A
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Total plasma 8-iso Prostaglandin F2α (8-isoprostane) was measured using a commercial 8-
Isoprostane EIA assay (Cayman Chemical). Briefly, plasma samples were collected in 
vacutainers containing EDTA that was supplemented with 0.005% BHT to prevent 
spontaneous oxidative formation of 8-isoprostane. Total 8-isoprostane was determined by 
first hydrolyzing the samples, followed by affinity sorbent/column purification step. Total 8-
isoprostane content was then measured according to the assay kit protocol.  The assay of both 
free and bound isoprostanes was used as a substantial proportion of 8-isoprostanes, which are 
esterified in lipids, would not be detected by measurement of free isoprostane alone. 
(j) Analysis of results: 
The current studies had >80% power to detect 20% differences in both FBF and UVV 
responses between groups at P<0.05 level. 
Clinical characteristics of normal subjects and CHF patients were compared utilising non-
paired t-tests (2-sided) for normally distributed parameters, and Wilcoxon tests for skewed 
data.  Categorical data were compared using a Fishers exact test.  Serial changes in FBF and 
UVV, pH and venous O2 saturation, and concentrations of NO2- and protein-bound NO in 
both the infused and non-infused forearms were compared in normal and CHF subjects by 
two-way ANOVA with repeated measures, utilizing Dunnett’s t-test to assess for significance 
of changes at individual time points.  Logit transformation of data was utilized to detect 
possible disparity of concentration-response relationships between groups of subjects.  All 
results are expressed as mean +/- SEM unless otherwise stated.  p-value of <0.05 was taken 
as statistically significant. 
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RESULTS 
 
Subject/Patient Characteristics 
The characteristics of the patients and healthy controls are detailed in Table 1 and the drug 
therapy in patients in Table 2.   It should be noted that although no patient had calculated 
creatinine clearance values less than 30 mls/minute, mean plasma creatinine levels were 
marginally abnormal in the CHF group, typical of populations with heart failure. 
 
Hemodynamic effects of nitrite infusion 
Sodium nitrite infusion was well-tolerated. Mean arterial blood pressure and heart rate did not 
vary significantly during the experiment:  mean arterial pressure values for normal subjects 
were 88 ± 4 mmHg and 88 ± 15 at baseline and peak nitrite infusion, respectively.  For CHF 
patients the mean arterial pressure values were 73 ± 4 and 70 ± 8 mmHg at baseline and peak 
nitrite infusion, respectively, while the corresponding values for heart rate were 62 ± 5 and 65 
± 4 beats/minute in normal subjects and 66 ± 4 and 69 ± 4 beats/minute in CHF patients.  
Maximal venous methemoglobin concentrations in the infused arm were less than 2% of total 
haemoglobin at all nitrite infusion rates. 
 
FBF changes are shown in Figure 2. In the non-infused forearm, both in normal subjects and 
CHF patients, there was significant vasoconstriction during the course of the study (ANOVA: 
F=2.6; p=0.04) which was attenuated at the highest nitrite infusion rate, raising the possibility 
of the onset of NO2- induced vasodilatation due to recirculation (Inset, Figure 2) . In the 
infused arm (main graph, Figure 2), the relationship between infusion rate and effect varied 
markedly between groups. For normal subjects, there was a progressive increase in FBF with 
infusion rates of 3.14 µmoles/min and higher.  In CHF patients, vasodilator responses were A
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induced already at the lowest infusion rates of nitrite, but with similar responses at doses 
>3.14 µmoles/min. Logit transformation of concentration-response data confirmed that the 
gradients of the linearised relationships were significantly steeper (p=0.017) in normal 
subjects than in CHF patients; partitioned ANOVA methodology was therefore utilized for 
analysis of these data. At lower, but not higher, infusion rates there were considerably greater 
FBF responses (F=5.5; p=0.02) than those in normal subjects, in whom the threshold for 
increases in FBF was NO2- infusion rate of 3.1µmoles/min. 
 
Unstressed venous volume (UVV) changes are summarised in Figure 3. In the non-infused 
arm (inset), both in normal subjects and patients, there was venoconstriction (F=9.6; 
p<0.0001) which was more marked in normal subjects (F= 15.4;p<0.001)).  In the infused 
arm (main graph, Figure 3), both groups exhibited evidence of increases in UVV 
commencing with the lowest infusion rate of sodium nitrite infusion, with a monophasic and 
progressive dose-related increase in UVV. However, overall responses in CHF patients were 
substantially lower than those in normal subjects (F=6.3; p=0.01). 
 
Changes in venous pH and O2 saturations 
pH in venous blood did not vary significantly between normal subjects and CHF patients, nor 
did it fluctuate significantly (Figure 4) during nitrite infusion in either arm. Venous oxygen 
saturation also did not vary significantly between patient groups (p= 0.27 and p=0.35 for 
changes in the CHF group versus healthy controls in the non infused and infused arms, 
respectively).  With nitrite infusion there was a trend to lower venous oxygen saturation with 
time in the non infused arm (p=0.07) which may be explained by prolonged immobility and 
consecutive decreases in blood flow with time.  In comparison in the infused arm there was 
no significant change in venous oxygen saturation with time (p= 0.53).  At peak dose venous A
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oxygen saturations were 79.5% ± 7.2 and 83.4 ± 1.8 in the CHF and healthy volunteers, 
respectively. 
 
Plasma NO2- and nitrate concentrations 
Changes in NO2- concentrations in venous blood during nitrite infusion are summarised in 
Figure 5A and 5B.  Resting plasma NO2- concentrations did not differ statistically between 
groups (0.60 ±.0.07 vs 0.41 ± 0.08 µM in control vs CHF patients:  p=0.08). NO2- 
concentrations did not change much in venous blood in the non-infused arm in both normal 
subjects and CHF patients (Figure 5A), but revealed a trend towards greater levels 
(F=4.3;p=0.04) in the normal subject group. 
In the infused arm (Figure 5B), NO2- concentrations increased approximately 70-fold during 
nitrite infusion (F=32.7;p<0.0001).  In normal subjects, venous nitrite concentrations 
increased from 1.2 ± 0.10 to 54.9 ± 16.5 µM, while in CHF patients the increase was from 
0.39 ± 0.07 to 29.0 ± 9.3  µM.  Thus, the increase in venous NO2- levels was greater in 
normal subjects than in CHF patients (F=10.6;p=0.002).  The increase in venous NO2- 
concentrations per 10-fold increase in nitrite infusion rate was disproportionately small: 
approximately 7-fold for normal subjects and 3-4 fold for CHF patients. 
Consistent with previous observations (Usui et al., 1998) basal nitrate levels in the venous 
effluent were found to be higher in the CHF patients compared to healthy volunteers (Figure 
6B; p=0.0034).  Venous nitrate levels rose similarly (p= 0.96 and p=0.67 for the non infused 
and infused arms respectively) in the two groups of subjects (Figure 6A and 6B) suggesting 
that the degree of oxidation of nitrite to nitrate did not differ between groups. 
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Protein-bound NO concentrations 
In the non-infused arm (Figure 7A), protein-bound NO concentrations were significantly 
greater in normal subjects than in patients with CHF (F=8.6; p=0.04).  In the infused arm, this 
difference was attenuated during nitrite infusion, becoming non-significant. Furthermore, 
protein-bound NO tended to increase with the highest nitrite infusion rate. 
 
Assessment of in vitro Nitrite Clearance in Human Plasma  
Following spiking of whole blood with nitrite in vitro plasma nitrite decayed similarly (p= 
0.66) in the two groups, with an apparent half-life of 5-6 min, irrespective of the initial 
concentration of nitrite achieved, as summarised in Figure 8.   Although basal levels of nitrate 
were higher in heart failure patients, the accompanying rate of nitrate formation was similar 
(p=0.99) in the two groups (not shown). Fitting attempts revealed that the reaction obeyed 
neither first nor second order kinetics suggesting the involvement of multiple processes 
including uptake, oxidation, reduction and redistribution between plasma and erythrocytes. 
 
In vitro tolerance/cross-tolerance study: 
In pre-constricted saphenous vein rings in vitro, nitrite induced vasorelaxation with a bi-
sigmoidal concentration-response characteristic (Figure 9). After exposure to very high 
concentrations of nitrite (10-2M) for 45 minutes followed by 30 minutes washout, there was 
no significant shift in the nitrite concentration-response curve (log EC50 for the low-affinity 
components -3.7±0.10 vs -4.0±0.08 M (n=7; p=NS, for before and after attempted tolerance 
induction, respectively). Furthermore, there was no cross-tolerance to GTN (log EC50 -
7.9±0.09 vs -7.9±0.07 M; n=7, p=NS for before and after nitrite tolerance induction, 
respectively).  A
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Assessment of nitrite infusion on oxidative stress 
Plasma total isoprostane levels (Figure 10) did not increase significantly with nitrite infusion 
in both normoxia and hypoxia (8.99±1.71, 7.07±0.93, 11.11±2.11 and 9.09±1.48 at baseline, 
“low-dose nitrite”, “higher-dose nitrite” and during hypoxia respectively. (P=0.44)). 
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DISCUSSION 
Previous studies, have suggested that infused nitrite exerts vasomotor responses that are 
similar to those of the organic nitrates, with marked venodilatation, and moderate dose-
dependent arteriolar dilatation, but in the case of nitrite these effects are augmented by 
hypoxia or exercise. (Cosby et al., 2003; Maher et al., 2008).  On the other hand, infused 
NO2- represents in many ways a particularly attractive agent for treatment of CHF 
complicated by fluid overload.  Not only is it a potent venodilator, but its effects appear to be 
(somewhat surprisingly) devoid of tolerance development (Dejam et al., 2007). Furthermore, 
NO2- provides a “needs-based” vasodilator effect, with effects accentuated by hypoxia in 
many systems (Ingram et al., 2010; Milsom et al., 2010; Shiva et al., 2007). The precise 
mechanism(s) underlying this accentuated effect remain incompletely understood. 
 
In the present study, effects of nitrite infusion were compared in normal subjects and patients 
with stable CHF.  The previously documented (Maher et al., 2008) selective venodilator 
effects of NO2- at low infusion rates was again documented in normal subjects: the lowest 
two infusion rates of nitrite induced significant increases in UVV, without increasing FBF. 
On the other hand, in CHF patients marked and selective hyper-responsiveness of forearm 
resistance vessels to lower rates of NO2- infusion was observed, with substantially reduced 
venodilator responses in CHF patients. The latter finding may represent NO resistance at the 
level of the capacitance bed. Alternatively it may be a consequence of increased clearance of 
NO2- across the vascular bed, resulting in lower concentrations in the capacitance vasculature 
at any given infusion rate (see below). Thus the main implication of the current findings is 
that in the presence of CHF the spectrum of vasomotor responses to nitrite is altered, with 
enhancement of arteriolar dilatation, but attenuation of venodilator responses. A
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The finding that CHF-patients had lower protein-bound NO and marginally lower nitrite 
concentrations than normal subjects is consistent with previous findings in subjects with 
endothelial dysfunction (Heiss et al., 2006; Kleinbongard et al., 2003; Lauer et al., 2001).  
Steady-state NO2- concentrations (in the absence of dietary or intravenous NO2- 
supplementation)  may be regarded as being indicative of NO generation  and therefore 
indicative of diminished eNOS activity in CHF (Lauer et al., 2001), whereas protein-bound 
NO concentrations reflect the generation of S-nitrosoproteins  from either NO or nitrite 
(Bryan et al., 2005), as well as a measure of prevalent redox stress (Ng et al., 2004). With 
sodium nitrite infusion, venous NO2- concentrations increased, but not in proportion to the 
increases in infusion rates, suggesting some selective loss of NO2- at higher infusion rates. 
These changes were noted both in the infused and non-infused arms, indicating that the non-
infused arm cannot be regarded as a simple “control” site: indeed the FBF changes (Figure 2, 
Inset) suggest the onset of some dilator effect with the highest nitrite infusion rate. 
Furthermore, NO2- levels increased far less markedly with increasing sodium nitrite infusion 
rates in CHF patients compared to normal subjects (Figure 5B) indicating greater rates of 
NO2- clearance in these patients. Although NO2- may be reduced to NO (bio-activation), a 
major clearance mechanism for NO2- is oxidation to nitrate. Therefore, venous nitrate 
concentrations were measured in both infused and non-infused arms, revealing that, in the 
presence of predominant oxidation of nitrite to nitrate, there was nevertheless a similar 
increase in plasma nitrate levels in the two groups upon infusion of nitrite, making enhanced 
clearance through oxidation to nitrate less likely to account for these differences.  Similarly, 
our in vitro results suggest that there is no systematic difference in the rate of nitrite 
disappearance in the two groups, thus excluding sampling artefacts as a possible explanation 
for the differences in nitrite concentrations between normal subjects and CHF-patients. A
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As regards the additional potential formation of S-nitrosoproteins via NO2- metabolism, 
venous protein-bound NO concentrations tended to increase in the infused arm in the CHF 
patients (coupled with a relative decrease in protein-bound NO concentrations in the 
controls), attenuating the difference between baseline levels in the two groups. These findings 
are also consistent with selective bio-activation of NO2- in the CHF patients, and might have 
been accounted for by the presence of tissue hypoxia and/or acidosis in these patients, given 
the previously described incremental bio-activation of NO2- in the presence of hypoxia 
(Maher et al., 2008). However, neither venous blood pH nor oxygen concentrations differed 
significantly between groups. There was a trivially (non- significantly) lower venous oxygen 
saturation in the infused arm of the heart failure patients, but this seems unlikely to provide 
an explanation for the difference in clearance. It therefore appears either that a component of  
subcellular/microvascular hypoxia was present in the CHF patients without detection in 
venous samples (a possible but somewhat unlikely event) or that these results indicate that, 
apart from hypoxia, NO2- bioactivation to NO can be induced by factors other than hypoxia, 
such as changes in redox state. This issue is worthy of further investigation.  
Taken together, these results show that CHF patients are hyper-responsive to the arteriolar 
dilating effects of infused sodium nitrite, presumably due to increased release of NO (despite 
the absence of arterial hypoxaemia). This finding may imply the need for some caution in the 
use of infused nitrite preparations in patients with decompensated CHF, for fear of 
precipitating falls in systolic blood pressure. On the other hand, symptomatic hypotension 
was not observed in the currently studied patient cohort. However, CHF patients were 
hyporesponsive both to the effects of infused sodium nitrite on venous capacitance and, to a 
lesser extent, to the effects on FBF at high infusion rates. These findings may imply the 
existence of NO resistance, as previously documented in both arteries and platelets of such A
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patients (Anderson et al.,2004). Although platelet NO resistance exhibits partial 
responsiveness to ACE inhibitor therapy (Chirkov et al., 2004), which was utilized in the 
majority of the CHF group, its interaction with vascular NO resistance is less certain. 
Alternatively, the apparent resistance of the capacitance vessels may in whole or in part be 
due to a lower concentration of nitrite in venous blood due to the increased transvascular 
clearance. This would potentially result in higher doses being required when treating heart 
failure patients acutely. As net responsiveness to NO2- reflects both accelerated bioactivation 
and diminished tissue responses to NO, it is likely that individual responses vary markedly, 
according to each of these component factors. 
 
Nitrate therapy is associated with the development of tolerance and increased oxidative 
stress. It is now accepted that a central component of nitrate tolerance induction is 
progressive failure of enzymatic bioactivation (Sage et al., 2000), and although the nature of 
the relevant nitrate reductase remains controversial (D'Souza et al., 2011), it is clear that 
GTN inhibits aldehyde dehydrogenases (ALDH)  (Chen et al., 2002 ; D'Souza et al., 2011; 
Towell., et al. 1986). In particular, the possibility that inhibition of the predominantly 
mitochondrial form of ALDH may contribute to nitrate tolerance development (and possibly 
also to accentuation of redox stress) has been the subject of considerable recent investigation 
(Chen et al.,  2002; Mackenzie et al,. 2005). Given that the bioactivation of nitrite is 
catalysed by a large number of nitrite reductases, which may include ALDH (Feelisch et al., 
2008), there is a theoretical potential both for the induction of tolerance after prolonged 
administration of nitrite and for the associated induction of redox stress. We therefore 
evaluated the potential for nitrite tolerance induction utilising cross-tolerance to GTN, a 
relevant issue given that this may theoretically develop after prolonged exposure to the agent 
(Henry et al,. 1990). Under the conditions of this experiment, nitrite did not induce tolerance A
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to itself (consistent with the findings of Dejam et al., 2007) or to GTN. Furthermore, 
prolonged systemic administration of nitrite in patients with CHF was not associated with 
aggravation of redox stress, as measured by plasma concentrations of total isoprostanes. On 
the other hand, it is possible that oxidative modification of proteins may have occurred. 
 
A number of potential limitations and caveats apply to the current findings. Most importantly, 
the biochemical basis of the observed arterial hyper-responsiveness to NO2- was not 
determined, and indeed the possible relevance of tissue hypoxia to this phenomenon cannot 
be completely excluded with the methodology utilised in this study. Furthermore, changes in 
tissue redox stress were not documented: this remains a major priority for future 
investigations. While the observation of attenuation of the increase in plasma NO2- in 
association with increasing rates of sodium nitrite infusion implies accelerated transvascular 
clearance of NO2- in such patients, the release of NO was not measured and nitrate generation 
data were incomplete for normal subjects. Therefore, it cannot be absolutely certain that there 
was a close relationship between such accelerated clearance and incremental rates of NO 
generation. Indeed, there is recent evidence that nitrite may exhibit vasoactivity independent 
of bioconversion and that nitrite may exert a component of its effects independent of the 
formation of NO or NO adduct (Bryan et al., 2005; Shiva and Gladwin, 2009).   Quantitation 
of heme-nitrosyl adducts in red blood cells and/or identification of specific NO adducts in 
plasma might have provided an additional, more direct index of NO formation,  However, as 
observed by Dejam et al (2007), increases in concentrations of such adducts are likely to 
parallel those of plasma nitrite concentrations.  Furthermore, the precise proportion of nitrite 
clearance via oxidation to nitrate cannot be assessed completely from the current results, 
although it was possible to exclude the possibility that transvascular nitrate generation 
occurred selectively in CHF patients given the similar rise in nitrate levels.  A
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Oxidative stress is associated with many chronic diseases and oxidative damage markers can 
be measured in the plasma. However, plasma measurement of oxidative stress remains a 
challenging area of research because of the highly reactive nature of these molecules. Several 
studies have focused on measuring either the total antioxidant capacity of plasma or specific 
measures of free radical-mediated damage such as F2-isoprostane or oxidised-LDL (Ox-
LDL). While we acknowledge that other oxidative stress markers could have been assessed in 
the current study, we opted to quantify total 8-isoprostane (8-iso Prostaglandin F2α). 
Isoprostanes are among the most reliable markers of oxidative stress that can be assessed in 
translational studies by specific immunoassay-based techniques. Moreover, these products 
are not only byproducts of oxidative stress, but also effector molecules involved in 
pathophysiology. 8-isoprostane is a potent pulmonary and renal vasoconstrictor and has been 
implicated as a causative mediator of hepato-renal syndrome and pulmonary oxygen toxicity. 
Finally, the findings of the current investigation, while relevant to the potential therapeutic 
administration of nitrite, may not be indicative of physiological modulation of NO2- at far 
lower concentrations. 
While NO2- infusion has the potential to lead to the generation of methemoglobin, (a possible 
concern) we did not observe a significant increase in venous methemoglobin levels in this 
study.  
We noted a significant vasoconstriction in the non-infused arm during the study.  In theory 
this could have been secondary to hypotension, however no significant drop in blood pressure 
was observed; in fact, there appeared to be a trend towards an increase.  It has been our 
experience in prolonged intrabrachial infusion studies with other agents that forearm blood 
flow falls in the contralateral arm over time despite no significant changes in blood pressure. 
We suspect this result from the effects of slight discomfort and often a full bladder during A
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these long studies.  It is because of such changes in flow in the non infused arm during 
prolonged studies that bilateral plethysmography with correction for the non infused arm is 
recommended for intrabrachial infusion studies (Benjamin et al., 1995). 
With regards to the medication received by the CHF patients, while there are data to suggest 
that angiotensin converting enzyme inhibitors and angiotensin receptor blockers improve NO 
production/ endothelial function we could not find any evidence to suggest any impact upon 
nitrite conversion.  The possibility that the medication taken by the CHF patients may 
account for some of the differences observed remains a limitation of this study. 
In the current study, nitrite was infused intra-arterially in order to document peripheral 
vasomotor responsiveness with minimal changes in systemic blood pressure.  This 
circumstance differs both from the potential mode of treatment to increase nitrite effect in 
chronic heart failure (for example via administration of dietary sources of nitrate) and from 
the intravenous infusion of nitrite as a component of management of acute heart failure.  
Nevertheless, the findings of the current investigation extend the question of the potential 
clinical utility of NO2- as a component of the management of patients with both acute and 
chronic heart failure. The major residual issue to be explored is the extent of change in 
vascular responsiveness to be seen in such patients, especially in decompensated CHF, where 
significant tissue hypoxia is more likely to be present,  with resultant potentiation of NO2--  
bio-activation, perhaps counter-balanced in part by the phenomenon of tissue resistance to 
NO (Chirkov and Horowitz 2007).  Despite the occurrence of NO resistance, treatment with 
organic nitrates is at least as effective as diuretic/morphine-based acute pharmacotherapy for 
decompensated heart failure with acute pulmonary oedema (Cotter et al., 1998; Sharon et al., 
2000).  However, nitrate therapy is often associated with the unpleasant side effect of 
headache.  In this study none of the subjects who received intravenous nitrite suffered from A
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this symptom, potentially providing a distinct advantage over traditional nitrate therapies. A 
comparison with NO2- based therapy now seems indicated.  
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Figure Legends 
Figure 1:  Schematic diagram of study protocol.   
Figure 2: Changes in Forearm Blood Flow (FBF) in the non-infused arm (Inset) and Infused 
arm in normal subjects (open symbols) and CHF patients (closed symbols). In the non-
infused arm, FBF decreased significantly (F=2.6;p=0.04); in the infused arm there was a 
selective increase in FBF associated with lower NO2- infusion rates (F=5.5;p=0.02).  * = p < 
0.05 vs normal subjects 
Figure 3: Changes in unstressed venous volume (UVV) in the non-infused arm (inset) and 
infused arm in normal subjects (open symbols) and CHF patients (closed symbols). In the 
non-infused arm, there was a decrease in UVV which was more marked in normal subjects 
(F=15.4;p<0.001). In the infused arm the increase in UVV with NO2- infusion was attenuated 
in CHF patients (F=6.2;p=0.01)..   
*= p < 0.05 vs normal subjects 
Figure 4: pH fluctuations in venous blood from (A) non-infused arm and (B) infused arm in 
normal subjects (open symbols) and CHF patients (closed symbols). pH did not vary 
significantly either with NO2- infusion rate or between groups. 
Figure 5: Venous plasma nitrite concentration (µM) in (A) non-infused arm and (B) infused 
arm in normal subjects (open symbols) and CHF patients (closed symbols).  Baseline nitrite 
concentrations were marginally lower in CHF patients than in normal subjects (p=0.08). 
Nitrite concentrations rose significantly (F=32.7;p<0.0001) with NO2- infusion in the infused 
arm: this increase  was attenuated significantly (F=10.6;p=0.002) in CHF patients.  * = p 
<0.05 vs normal subjects A
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Figure 6: Venous plasma nitrate concentrations in (A) non infused arm and (B) infused arm 
in normal subjects (open symbols) and CHF patients (closed symbols).  Baseline nitrate 
concentrations were greater (p=0.003) in CHF subjects.  During nitrite infusion, nitrate 
concentrations increased ( F=16.2 P<0.0001)) in the infused arm, but without significant 
difference between normal subjects and CHF patients. 
 
Figure 7:  Venous plasma protein-bound NO (RXNO:nmol/L)in (A) non-infused arm and 
(B) infused arm in normal subjects (open symbols)and CHF patients (closed symbols). 
RXNO concentrations did not vary significantly with NO2- infusion in either arm (F= 0.44 
p= 0.99), but were significantly lower in CHF patients than in normal subjects in the non-
infused arm (p=0.04), while this difference was attenuated in the infused arm. 
Figure 8:  Clearance of nitrite in vitro from human plasma.   Closed symbols represent data 
from normal subjects; open symbols represent data from CHF patients.  
Figure 9:   In vitro tolerance/cross-tolerance induction study. Concentration-response curves 
are shown for nitrite and GTN, indicating percentage relaxation of saphenous vein rings, 
before and after prolonged incubation with nitrite. 
Figure 10:  Plasma 8-isoprostane concentrations following nitrite infusion in heart failure 
patients. Values did not vary significantly between infused (A) and non-infused (B) arms. 
Table 1: Demographic data for both groups of subjects 
Table 2: Summary of the medication taken by the CHF patients.  
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Table 1 
 
Demographic and Clinical Features CHF Patients 
(mean±SEM) 
Healthy Controls 
(mean±SEM) 
P 
Value 
Age (y)  
Sex, M/F (%) 
Body mass index (kg/m2)  
Serum cholesterol (mmol/L)  
Plasma glucose (mmol/L)  
Serum Creatinine (µmol/l) 
Heart rate 
Blood pressure (mmHg) 
        Systolic 
        Diastolic 
Left Ventricular Ejection Fraction  
Aetiology (Ischaemic/DCM) 
62.9±2.7 
18/3 (86/14) 
30.0±1.2 
5.3±0.4 
5.8±0.4 
125±6.7 
74±2 
 
117±3.7 
74.8±1.9 
34.8±2.5 
10/11 
57.6±1.2 
15/5 (75/25) 
26.8±0.6 
5.4±0.2 
4.7±0.1 
103.4±5.2 
61.5±1.9 
 
128±2.0 
73.4±1.4 
56.6±1.7 
N/A 
0.08 
0.70 
0.05 
0.69 
0.05 
0.03 
0.01 
 
0.03 
0.73 
0.001 
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Table 2 
 
Medication % of patients receiving 
 
Beta blockers 
ACE Inhibitors / ARB 
Aldosterone Antagonists 
Loop diuretics 
 
Perhexiline 
Warfarin 
Antiplatelets 
‘Statins’ 
Digoxin 
 
 
76% 
95% 
 
57% 
100% 
 
 
29% 
57% 
 
48% 
52% 
 
19% 
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